Leading Chinese MedTech Firms in Diagnostics, Biomaterials, and Dental Seek Global Partnerships for International Expansion

As of now, VCBeat has launched the link.Nearly 1,000 entries, average clicks per link50+, Maximum Number of Successful Connections per Single Line>10 times。

Weekly curated series of collaborative linkscloth,Special Featurefor "Going Global"，Going GlobalAt that time, numerous domestic medical technology companiesexpand into the international market,Seeking Strategic Partners for Global Expansion。VCBeat has compiled medical testing, new materials,Dentistry and Other FieldsLeading enterprises in the sector are seeking overseas partners. Details are as follows:

●Company/Product Introduction：

Youyi Biotech is centered on clinical value, dedicated to the independent research and development, production, and sales of high-performance, reliable-quality, and automated novel in vitro diagnostic reagents, consumables, and equipment for pathology and laboratory testing. Its product portfolio spans molecular diagnostics, cytopathology, and artificial intelligence. The company has been recognized as a National High-Tech Enterprise in China, with its business direction aligned with strategic emerging industries that are prioritized for support by governments worldwide. Products that have obtained CE certification or Chinese registration certificates include series for thalassemia genetic testing, cervical cancer screening (HPV testing, cytology, and dual-staining), and urinary cytology testing.

●Collaboration Requirements:

Shenzhen Youyi Biotech is seeking agency enterprises, hospitals, or relevant individuals with overseas resources as strategic partners for international expansion, to jointly explore markets in Southeast Asia, the Middle East, South America, and other regions, and to facilitate the local adaptation of Youyi Biotech’s products.

●Company/Product Introduction:

1) Company Introduction: Jingze Biopharmaceuticals (Hefei) Co., Ltd. (hereinafter referred to as “Jingze Biopharm”) focuses on the fields of assisted reproduction and ophthalmology, dedicated to innovative R&D and industrialization by applying cutting-edge biotechnologies, with the aim of becoming an industry-leading enterprise.

2) Product Pipeline Progress

Within Jingze Biologics’ product pipeline, one product has submitted a New Drug Application (NDA) for recombinant human follicle-stimulating hormone for injection (rh-FSH), with approval of the production license expected in October 2024; three products have entered Phase III clinical trials; and three products have entered Phase I clinical trials.

●Cooperation Requirements:

1) Current Valuation and Funding Requirements

The closing of the Series C+ financing round was completed in March 2024 (RMB 380 million), officially entering the Pre-IPO stage, with a current valuation of RMB 2.9925 billion.

Funding Requirement: RMB 200 million to RMB 300 million, primarily to accelerate clinical trials of pipeline candidates and lay the groundwork for commercialization of related products.

2) IPO Planning (3+H)

Completed shareholding reform and listing tutoring; securities firms, law firms, and accounting firms have commenced on-site work. The company plans to pursue an IPO on the NEEQ by the end of 2024 and an H-share IPO in the first half of 2025.

3) BD Collaboration Intent

Seeking collaboration on overseas rights and distribution channels for the company’s current pipeline products and those with submitted New Drug Applications (NDAs).

●Company/Product Introduction：

1) Project Overview: The company is a high-tech enterprise specializing in the R&D, production, and sales of dental additive manufacturing equipment and materials. Leveraging ultra-fast, ultra-high-precision LCD photocuring technology as its core, it focuses on meeting the needs for immediate chairside dental treatment, thereby achieving leapfrog improvements in medical efficiency and patient experience.

2) Product Applications: Covers the entire field of dentistry, providing immediate production of therapeutic devices and implants such as orthodontic aligners, surgical guides for dental implants, whitening veneers, and denture bases.

3) Core Technologies: Proprietary liquid-cooled LCD photopolymerization technology overcomes thermal barrier bottlenecks, maintaining the world record for fastest printing speed while achieving industry-leading accuracy and resolution. The company has mastered fully in-house, closed-loop core technologies spanning software, hardware, and materials (CE and FDA certified), resolving supply chain vulnerabilities for critical components and significantly reducing equipment costs. With over 40 core patents, the company maintains robust global patent protection.

4) Team Background: The founder holds a degree in Materials Science from Tsinghua University, and the core team members are all graduates of prestigious Chinese universities specializing in science and engineering. The team possesses over 10 years of profound technical expertise and a proven track record of success in the field of photocuring technology.

●Collaboration Requirements:

The product has been validated in overseas markets, with over 95% of its customers located abroad, and it has successfully entered the distribution networks of leading distributors in Europe and the United States. The company is currently seeking further international partners.

●Company/Product Introduction：

Lixin Science – Dedicated to the development and research of a technology platform for absorbable, regeneration-inducing biomaterials. Lixin has achieved a fully domestic, closed-loop solution covering the entire industrial chain of regenerative biomaterials. Its technologies and products serve medical fields such as orthopedics, sports medicine, dentistry, and medical aesthetics and plastic surgery, with the ambition to become a global leader in the regenerative medical device industry.

The world’s first moldable, anti-disintegration regenerative artificial bone. Nuwa Stone regenerative artificial bone was launched in the U.S. market in February 2023 and is currently undergoing registration in multiple countries worldwide. Leveraging the company’s proprietary ultra-dispersed hydroxyapatite/polylactic acid composite material technology, the product has achieved global breakthroughs in its characteristics, primarily including:

1. Moldable and adaptable to bone defects of any shape, greatly facilitating the surgical procedure;

2. Resistant to liquid-phase disintegration, it can maintain stable shaping without disintegrating in water or blood, and assist in achieving immediate hemostasis at bone defect sites;

3. Efficient bone regeneration, enabling material degradation and bone regeneration within 3–6 months postoperatively, facilitating regenerative repair of bone defects in patients.

●Cooperation Requirements:Seeking overseas distributor resources, primarily in markets including North America, South America, Southeast Asia, the Middle East, and the Commonwealth of Independent States (CIS).

●Company/Product Introduction：

Provides products and services covering the entire therapeutic cycle of reproductive health, from prevention, diagnosis, and treatment to prognosis management, including clinical diagnostic reagents and equipment, complete laboratory solutions with reagents and consumables, information technology infrastructure plans, and a range of follow-up services.

●Cooperation Requirements:Connect with established local distributors and agents to facilitate product certification and expand market channels.

●Company/Product Introduction：

Yangqi Medical Chip’s products primarily focus on the field of Surface Guided Radiation Therapy (SGRT), including the surface monitoring product “QiShi” and the low-dose CT enhancement product “QingYing.” By innovatively introducing non-contact tumor imaging technology, the system scans the patient’s body surface to acquire three-dimensional shape and positional information of the tumor without introducing additional radiation dose, thereby achieving high-precision localization. This assists physicians in formulating more accurate radiotherapy plans, ensuring that radiation is delivered exclusively to tumor tissue while minimizing damage to surrounding healthy tissues.

●Cooperation Requirements:

Planning to obtain CE certification; seeking professional regulatory and policy support to expedite the process. European agents are welcome to contact us.

●Enterprise/Product Introduction：

1) Company Introduction: Infome focuses on the vertically integrated field of comprehensive kidney diseases, aiming to build a 360° all-around data management platform.

2) Project Introduction: This Class III innovative medical device features independent intellectual property rights and is the only product globally to have obtained certification for a Class III innovative medical device software registration certificate. It is currently primarily applied in the technical fields of precise prescription dosing, monitoring, and assessment of key indicators in blood purification therapy. With advantages such as being non-invasive, real-time, continuous, and user-friendly, it is a digital product that enhances the level of clinical diagnosis and treatment. Representing new technology and new directions, it holds immense market potential.

●Collaboration Requirements:

Seeking Partners. Possessing client channels with multinational corporations (MNCs), experienced in collaborating on MNC projects, and familiar with the operation of overseas intellectual property or product licensing projects.

●Company/Product Introduction：

Shudan Medical’s Brain Renewal Neuroprotective Glasses are the first marketed product in China to utilize Gamma audiovisual stimulation to improve brain function, and also the first product in China to achieve clinical validation of the effectiveness of home-based Gamma audiovisual intervention.

Cerebral Renewal Neuroprotective Glasses: Alleviate mental fatigue after just one hour of use, improve sleep quality within seven days, and enhance cognitive function in three months. The product has currently obtained certifications from relevant authorities in China, the European Union, and the United States, making it available for global sale. Furthermore, hundreds of efficacy data points and user feedback reports have been accumulated from both in-hospital and out-of-hospital settings.

●Collaboration Requirements:Seeking cross-border e-commerce partners with extensive sales channels for this category of products.

●Company/Product Introduction：

GenoCare has mastered the critical “chokepoint” technologies and processes for gene sequencers, established its proprietary “SURFseq” sequencing technology system, and holds over 400 patents granted or pending in China and abroad.

Achieved independent domestic R&D and production of sequencers and core raw materials, including tool enzymes, nucleotide analogs, fluorescent dyes, and sequencing chips, enabling the provision of a comprehensive “instrument–reagent–chip–software” platform solution.

●Cooperation Requirements:

Genetron Health (Shenzhen) is seeking industrial and research clients, agents and distributors, as well as investment, financing, and overseas resource partnerships.

●Company/Product Introduction：

Reindeer Bio is dedicated to the research and development, manufacturing, and commercialization of innovative cell-based therapies. Guided by its vision of “bringing hope for a cure to patients,” the company has achieved leapfrog growth over the seven years since its establishment. Reindeer Bio currently has more than 10 product candidates in its pipeline. With the development of cellular therapies and antibody drugs for hematologic malignancies as its innovation foundation, the company is expanding into autoimmune diseases. Its portfolio not only holds promise for addressing unmet needs in both domestic and international markets but also has the potential to become internationally leading therapeutics for related diseases, offering patients more effective and safer treatment options.

●Collaboration Requirements:

1) Overseas Expansion Plan: Southeast Asia, South Korea, Russia, the Middle East, Central Asia, and other regions.

2) Requirements for service providers: Partners with local commercialization capabilities in hematologic oncology, capable of facilitating clinical access, market sales, and related operations.

- VCBeat’s Supply and Demand Matching Platform covers: global expansion, supply chain, marketing/channels, technology transfer, and investment promotion.

- Upload supply or demand resources to the platform to precisely reach targeted prospective partners

- Efficiently connect with entities such as multinational corporations (MNCs), startups, government industrial parks, and investment institutions